CYP2C19 gene combined with platelet function detection to guide anti-platelet study after complex PCI

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043438

Enrollment

Unknown

Registered

2021-02-18

Start date

2021-02-22

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Group B:The combination of Cyp2C19 gene detection and platelet aggregation rate

Group B:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Complex coronary artery lesions (including CTO lesions, left main artery lesions, bifurcation lesions, three-vessel lesions, slow or no reflow after stenting, and lesions with more than 3 stents in a single implantation).

Exclusion criteria

Exclusion criteria: 1. Received P2Y12 receptor antagonist therapy within the past 30 days; 2. Have contraband of ticagrelor or clopidogrel or drug allergy; 3. Active bleeding, previous history of intracranial hemorrhage, history of gastrointestinal bleeding within 6 months, and history of major surgery within 30 days; 4. Moderate and severe liver disease, coagulation dysfunction, and malignant tumor; 5. Severe renal insufficiency; 6. Coronary artery bypass grafting is planned in the near future.

Design outcomes

Primary

Measure	Time frame
MACE event;	—

Countries

China

Contacts

Public ContactYu Jiancai

Second Department of Cardiology, Cangzhou Central Hospital

598793744@qq.com+86 18003279273

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026